Competition & Antitrust.
Merger review run as a litigation, not a filing.
The work — Merger review where the agency has already decided it has a problem, and conduct investigations where a complaint is a realistic outcome. We build the record from day one as though we will be defending it at trial, because in a close matter that is exactly what happens.
What we cover — Second requests at the FTC and the DOJ Antitrust Division. Phase II review before the European Commission and the CMA. Cartel investigations, leniency applications and grand jury exposure. Follow-on damages claims and standalone abuse-of-dominance actions. Competitor joint ventures and information-exchange protocols that survive a later challenge.
How we work — The economic model and the deal documents are authored together. Outside economists who have never read the board deck write models that do not survive cross-examination, because the cross is built from the documents. We hold a credible no-divestiture position until the evidence says otherwise: once a carve-out is floated, even informally, it becomes the floor and it grows. Where a second regulator is reviewing the same transaction, the two submissions say the same thing — market definition, theory of harm, witness statements.
Recent matter — A US-listed therapeutics company through a contested FTC second request and parallel European Commission review of an overlapping oncology pipeline. Cleared without remedies. Closed on the original timetable.
